{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:30:02Z","timestamp":1782246602944,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04409-1","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T08:32:37Z","timestamp":1739349157000},"page":"2181-2194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary procedures: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Ayesha Imran","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazila","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukaina","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. N. U.","family":"Namal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawood","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassaan","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Hudaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab Safdar Ali","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asadullah","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umer","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ebad Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huzaifa Ahmad","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Husnain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Anwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Mohid","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeh Ur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheel","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"4409_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/859328","author":"FG Meinel","year":"2014","unstructured":"Meinel FG, De Cecco CN, Schoepf UJ, Katzberg R (2014) Contrast-induced acute kidney injury: definition, epidemiology, and outcome. BioMed Res Int. https:\/\/doi.org\/10.1155\/2014\/859328","journal-title":"BioMed Res Int"},{"issue":"4","key":"4409_CR2","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1111\/j.1523-1755.2004.00927.x","volume":"66","author":"RL Mehta","year":"2004","unstructured":"Mehta RL, Pascual MT, Soroko S et al (2004) Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 66(4):1613\u20131621. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00927.x","journal-title":"Kidney Int"},{"key":"4409_CR3","unstructured":"Modi K, Padala SA, Gupta M. Contrast-induced nephropathy. In: StatPearls. StatPearls Publishing; 2024. Accessed December 18, 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448066\/"},{"issue":"2","key":"4409_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10557-015-6635-0","volume":"30","author":"G Chalikias","year":"2016","unstructured":"Chalikias G, Drosos I, Tziakas DN (2016) Contrast-induced acute kidney injury: an update. Cardiovasc Drugs Ther 30(2):215\u2013228. https:\/\/doi.org\/10.1007\/s10557-015-6635-0","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"4409_CR5","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/s0002-9343(97)00150-2","volume":"103","author":"PA McCullough","year":"1997","unstructured":"McCullough PA, Wolyn R, Rocher LL, Levin RN, O\u2019Neill WW (1997) Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103(5):368\u2013375. https:\/\/doi.org\/10.1016\/s0002-9343(97)00150-2","journal-title":"Am J Med"},{"key":"4409_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004439","author":"JA Valle","year":"2017","unstructured":"Valle JA, McCoy LA, Maddox TM et al (2017) Longitudinal risk of adverse events in patients with acute kidney injury after percutaneous coronary intervention: insights from the national cardiovascular data registry. Circ Cardiovasc Interv. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004439","journal-title":"Circ Cardiovasc Interv"},{"key":"4409_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1161-5","author":"Y Yang","year":"2018","unstructured":"Yang Y, George KC, Luo R et al (2018) Contrast-induced acute kidney injury and adverse clinical outcomes risk in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. BMC Nephrol. https:\/\/doi.org\/10.1186\/s12882-018-1161-5","journal-title":"BMC Nephrol"},{"key":"4409_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.116.004383","author":"D Giacoppo","year":"2017","unstructured":"Giacoppo D, Gargiulo G, Buccheri S et al (2017) Preventive strategies for contrast-induced acute kidney injury in patients undergoing percutaneous coronary procedures: evidence from a hierarchical bayesian network meta-analysis of 124 trials and 28 240 Patients. Circ Cardiovasc Interv. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.116.004383","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"4409_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.amjcard.2009.09.026","volume":"105","author":"A Toso","year":"2010","unstructured":"Toso A, Maioli M, Leoncini M et al (2010) Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol 105(3):288\u2013292. https:\/\/doi.org\/10.1016\/j.amjcard.2009.09.026","journal-title":"Am J Cardiol"},{"issue":"2","key":"4409_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/s0735-1097(02)01958-7","volume":"40","author":"C Briguori","year":"2002","unstructured":"Briguori C, Manganelli F, Scarpato P et al (2002) Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40(2):298\u2013303. https:\/\/doi.org\/10.1016\/s0735-1097(02)01958-7","journal-title":"J Am Coll Cardiol"},{"key":"4409_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000517991","author":"YF Zhang","year":"2021","unstructured":"Zhang YF, Liu DD, Zhou Y, Lou JZ (2021) Acute kidney injury in patients with acute coronary syndrome after percutaneous coronary intervention: pathophysiologies, risk factors, and preventive measures. Cardiology. https:\/\/doi.org\/10.1159\/000517991","journal-title":"Cardiology"},{"issue":"5","key":"4409_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4103\/ijp.IJP_298_19","volume":"51","author":"LA Ahmed","year":"2019","unstructured":"Ahmed LA (2019) Nicorandil: a drug with ongoing benefits and different mechanisms in various diseased conditions. Indian J Pharmacol 51(5):296\u2013301. https:\/\/doi.org\/10.4103\/ijp.IJP_298_19","journal-title":"Indian J Pharmacol"},{"key":"4409_CR13","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00263.2007","author":"Z Sun","year":"2008","unstructured":"Sun Z, Zhang X, Ito K et al (2008) Amelioration of oxidative mitochondrial DNA damage and deletion after renal ischemic injury by the KATP channel opener diazoxide. Am J Physiol Renal Physiol. https:\/\/doi.org\/10.1152\/ajprenal.00263.2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"4409_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.1476-5381.2011.01231.x","volume":"163","author":"S Shimizu","year":"2011","unstructured":"Shimizu S, Saito M, Kinoshita Y et al (2011) Nicorandil ameliorates ischaemia-reperfusion injury in the rat kidney. Br J Pharmacol 163(2):272\u2013282. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01231.x","journal-title":"Br J Pharmacol"},{"key":"4409_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/14.suppl_B.48","author":"E Roland","year":"1993","unstructured":"Roland E (1993) Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/14.suppl_B.48","journal-title":"Eur Heart J"},{"key":"4409_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001039","author":"JS Lawton","year":"2021","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S et al (2021) ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College Of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000001039","journal-title":"Circulation"},{"key":"4409_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/4527816","volume":"2020","author":"B Yi","year":"2020","unstructured":"Yi B, Mo S, Jiang Y et al (2020) Efficacy and safety of nicorandil in preventing contrast-induced nephropathy after elective percutaneous coronary intervention: a pooled analysis of 1229 patients. J Intervent Cardiol 2020:1\u20137. https:\/\/doi.org\/10.1155\/2020\/4527816","journal-title":"J Intervent Cardiol"},{"issue":"9","key":"4409_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.carrev.2020.01.010","volume":"21","author":"R Pranata","year":"2020","unstructured":"Pranata R, Vania R, Alkatiri AA, Firman D, Lukito AA (2020) Nicorandil reduces the incidence of contrast-induced nephropathy in patients undergoing coronary angiography\/intervention\u2013systematic review and meta-analysis of randomized controlled trials including GRADE qualification. Cardiovasc Revascularization Med Mol Interv 21(9):1121\u20131127. https:\/\/doi.org\/10.1016\/j.carrev.2020.01.010","journal-title":"Cardiovasc Revascularization Med Mol Interv"},{"issue":"7","key":"4409_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0003319717732237","volume":"69","author":"B Zhan","year":"2018","unstructured":"Zhan B, Huang X, Jiang L, Bao H, Cheng X (2018) Effect of nicorandil administration on preventing contrast-induced nephropathy: a meta-analysis. Angiology 69(7):568\u2013573. https:\/\/doi.org\/10.1177\/0003319717732237","journal-title":"Angiology"},{"key":"4409_CR20","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12975","author":"Z Mei","year":"2022","unstructured":"Mei Z, Luo S, Chen P et al (2022) Efficacy of brain natriuretic peptide vs nicorandil in preventing contrast-induced nephropathy: a network meta-analysis. Peer. https:\/\/doi.org\/10.7717\/peerj.12975","journal-title":"Peer"},{"key":"4409_CR21","doi-asserted-by":"publisher","unstructured":"Front Matter. In: cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Ltd; 2019:i-xxviii. https:\/\/doi.org\/10.1002\/9781119536604.fmatter","DOI":"10.1002\/9781119536604.fmatter"},{"key":"4409_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4409_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4409_CR24","unstructured":"Cochrane handbook for systematic reviews of interventions. Accessed July 5, 2024. https:\/\/training.cochrane.org\/handbook"},{"key":"4409_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijcard.2015.05.078","volume":"195","author":"T Nawa","year":"2015","unstructured":"Nawa T, Nishigaki K, Kinomura Y et al (2015) Continuous intravenous infusion of nicorandil for 4hours before and 24hours after percutaneous coronary intervention protects against contrast-induced nephropathy in patients with poor renal function. Int J Cardiol 195:228\u2013234. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.078","journal-title":"Int J Cardiol"},{"issue":"3","key":"4409_CR26","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MCA.0000000000001347","volume":"35","author":"J Yusuf","year":"2024","unstructured":"Yusuf J, Prakash G, Safal S, Mehta V, Mukhopadhyay S (2024) Efficacy of nicorandil and ranolazine in prevention of contrast-induced nephropathy in patients with mild-to-moderate renal dysfunction: a randomized controlled trial. Coron Artery Dis 35(3):186\u2013192. https:\/\/doi.org\/10.1097\/MCA.0000000000001347","journal-title":"Coron Artery Dis"},{"issue":"3","key":"4409_CR27","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MCA.0000000000000826","volume":"31","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yang S, Zhang P, Fu N (2020) Efficacy of nicorandil on the prevention of contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention. Coron Artery Dis 31(3):284\u2013288. https:\/\/doi.org\/10.1097\/MCA.0000000000000826","journal-title":"Coron Artery Dis"},{"issue":"5","key":"4409_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.5603\/CJ.a2017.0028","volume":"24","author":"L Iranirad","year":"2017","unstructured":"Iranirad L, Hejazi SF, Sadeghi MS, Jang SA (2017) Efficacy of nicorandil treatment for prevention of contrast-induced nephropathy in high-risk patients undergoing cardiac catheterization: a prospective randomized controlled trial. Cardiol J 24(5):502\u2013507. https:\/\/doi.org\/10.5603\/CJ.a2017.0028","journal-title":"Cardiol J"},{"issue":"6","key":"4409_CR29","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1159\/000503160","volume":"44","author":"Z Fan","year":"2019","unstructured":"Fan Z, Li Y, Ji H, Jian X (2019) Efficacy of oral nicorandil to prevent contrast-induced nephropathy in patients with chronic renal dysfunction undergoing an elective coronary procedure. Kidney Blood Press Res 44(6):1372\u20131382. https:\/\/doi.org\/10.1159\/000503160","journal-title":"Kidney Blood Press Res"},{"issue":"9","key":"4409_CR30","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s11255-023-03541-0","volume":"55","author":"A AbdollahiMoghaddam","year":"2023","unstructured":"AbdollahiMoghaddam A, BaradaranRahimi V, Morovatdar N, Rezaee R, Babalhekam SA (2023) Oral Nicorandil effectively attenuates the incidence of contrast-induced nephropathy in patients undergoing cardiac catheterization: a randomized, controlled, open-label clinical trial. Int Urol Nephrol 55(9):2327\u20132334. https:\/\/doi.org\/10.1007\/s11255-023-03541-0","journal-title":"Int Urol Nephrol"},{"key":"4409_CR31","doi-asserted-by":"publisher","DOI":"10.18926\/AMO\/61433","author":"H Otsuka","year":"2021","unstructured":"Otsuka H, Miyoshi T, Ejiri K et al (2021) Possible protective effect of remote ischemic preconditioning on acute kidney injury following elective percutaneous coronary intervention: secondary analysis of a multicenter. Randomized Study. https:\/\/doi.org\/10.18926\/AMO\/61433","journal-title":"Randomized Study"},{"issue":"11","key":"4409_CR32","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1007\/s00380-016-0809-y","volume":"31","author":"Y Fan","year":"2016","unstructured":"Fan Y, Wei Q, Cai J et al (2016) Preventive effect of oral nicorandil on contrast-induced nephropathy in patients with renal insufficiency undergoing elective cardiac catheterization. Heart Vessels 31(11):1776\u20131782. https:\/\/doi.org\/10.1007\/s00380-016-0809-y","journal-title":"Heart Vessels"},{"issue":"4","key":"4409_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3349\/ymj.2013.54.4.957","volume":"54","author":"YG Ko","year":"2013","unstructured":"Ko YG, Lee BK, Kang WC et al (2013) Preventive effect of pretreatment with intravenous nicorandil on contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography (principle study). Yonsei Med J 54(4):957. https:\/\/doi.org\/10.3349\/ymj.2013.54.4.957","journal-title":"Yonsei Med J"},{"key":"4409_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/0003319719841733","author":"P Zhang","year":"2020","unstructured":"Zhang P, Li W, yuan, Yang SC, et al (2020) Preventive effects of nicorandil against contrast-induced nephropathy in patients with moderate renal insufficiency undergoing percutaneous coronary intervention. Angiology. https:\/\/doi.org\/10.1177\/0003319719841733","journal-title":"Angiology"},{"key":"4409_CR35","doi-asserted-by":"publisher","DOI":"10.58675\/2682-339X.1724","author":"AEAM Ali","year":"2023","unstructured":"Ali AEAM, El-Yazal ISAEAS, Mansy AM (2023) Role of nicorandil effect on contrast induced nephropathy in patients land for elective PCI. Azhar Int Med J. https:\/\/doi.org\/10.58675\/2682-339X.1724","journal-title":"Azhar Int Med J"},{"key":"4409_CR36","unstructured":"Zhao K, Li YJ, Gao S. Role of oral nicorandil in preventing contrast induced nephropathy in type 2 diabetics undergoing coronary angiography"},{"issue":"8","key":"4409_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/imj.13962","volume":"48","author":"S Li","year":"2018","unstructured":"Li S, Wang L, Liu Y, Hu Q (2018) Preventive effect of nicorandil on contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Intern Med J 48(8):957\u2013963. https:\/\/doi.org\/10.1111\/imj.13962","journal-title":"Intern Med J"},{"key":"4409_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12316","author":"X Ma","year":"2018","unstructured":"Ma X, Li X, Jiao Z, Zhang Y (2018) Nicorandil for the prevention of contrast-induced nephropathy: a meta-analysis of randomized controlled trials. Cardiovasc Ther. https:\/\/doi.org\/10.1111\/1755-5922.12316","journal-title":"Cardiovasc Ther"},{"issue":"23","key":"4409_CR39","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1001\/jama.295.23.2765","volume":"295","author":"N Pannu","year":"2006","unstructured":"Pannu N, Wiebe N, Tonelli M (2006) Alberta kidney disease network FT. Prophylaxis Strategies for Contrast-Induced Nephropathy JAMA 295(23):2765. https:\/\/doi.org\/10.1001\/jama.295.23.2765","journal-title":"Prophylaxis Strategies for Contrast-Induced Nephropathy JAMA"},{"key":"4409_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118379","author":"F Zhang","year":"2020","unstructured":"Zhang F, Lu Z, Wang F (2020) Advances in the pathogenesis and prevention of contrast-induced nephropathy. Life Sci. https:\/\/doi.org\/10.1016\/j.lfs.2020.118379","journal-title":"Life Sci"},{"issue":"4","key":"4409_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/MAJ.0b013e318068ddf9","volume":"334","author":"O Toprak","year":"2007","unstructured":"Toprak O (2007) Risk markers for contrast-induced nephropathy. Am J Med Sci 334(4):283\u2013290. https:\/\/doi.org\/10.1097\/MAJ.0b013e318068ddf9","journal-title":"Am J Med Sci"},{"key":"4409_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/10742484231174296","author":"Z Yu","year":"2023","unstructured":"Yu Z, zhong, Xu Z xiong, Ruan Y hua, et al (2023) Protective effect of nicorandil on contrast-induced acute kidney injury after emergency percutaneous coronary intervention. J Cardiovasc Pharmacol Ther. https:\/\/doi.org\/10.1177\/10742484231174296","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"4409_CR43","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s13244-013-0291-3","volume":"4","author":"RWF Geenen","year":"2013","unstructured":"Geenen RWF, Kingma HJ, Van Der Molen AJ (2013) Contrast-induced nephropathy: pharmacology, pathophysiology and prevention. Insights Imaging 4(6):811\u2013820. https:\/\/doi.org\/10.1007\/s13244-013-0291-3","journal-title":"Insights Imaging"},{"key":"4409_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.pharmthera.2017.06.009","volume":"180","author":"C Mamoulakis","year":"2017","unstructured":"Mamoulakis C, Tsarouhas K, Fragkiadoulaki I et al (2017) Contrast-induced nephropathy: Basic concepts, pathophysiological implications and prevention strategies. Pharmacol Ther 180:99\u2013112. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.009","journal-title":"Pharmacol Ther"},{"key":"4409_CR45","doi-asserted-by":"publisher","DOI":"10.1177\/1179546819878680","author":"R Morcos","year":"2019","unstructured":"Morcos R, Kucharik M, Bansal P et al (2019) Contrast-induced acute kidney injury: review and practical update. Clin Med Insights Cardiol. https:\/\/doi.org\/10.1177\/1179546819878680","journal-title":"Clin Med Insights Cardiol"},{"issue":"21","key":"4409_CR46","doi-asserted-by":"publisher","first-page":"J18","DOI":"10.1016\/0002-9149(89)90200-2","volume":"63","author":"N Taira","year":"1989","unstructured":"Taira N (1989) Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 63(21):J18\u2013J24. https:\/\/doi.org\/10.1016\/0002-9149(89)90200-2","journal-title":"Am J Cardiol"},{"key":"4409_CR47","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-199206203-00002","volume":"20","author":"WR Kukovetz","year":"1992","unstructured":"Kukovetz WR, Holzmann S, P\u00f6ch G (1992) Molecular Mechanism of Action of Nicorandil: J Cardiovasc Pharmacol 20:S1-7. https:\/\/doi.org\/10.1097\/00005344-199206203-00002","journal-title":"Molecular Mechanism of Action of Nicorandil: J Cardiovasc Pharmacol"},{"issue":"9","key":"4409_CR48","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2165\/11592300-000000000-00000","volume":"71","author":"S Horinaka","year":"2011","unstructured":"Horinaka S (2011) Use of Nicorandil in Cardiovascular Disease and Its Optimization: Drugs 71(9):1105\u20131119. https:\/\/doi.org\/10.2165\/11592300-000000000-00000","journal-title":"Use of Nicorandil in Cardiovascular Disease and Its Optimization: Drugs"},{"key":"4409_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001117","author":"X Du","year":"2021","unstructured":"Du X, Ma Z, Li L, Zhong X (2021) Nicorandil decreases renal injury in patients with coronary heart disease complicated with type i cardiorenal syndrome. J Cardiovasc Pharmacol. https:\/\/doi.org\/10.1097\/FJC.0000000000001117","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9348","key":"4409_CR50","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(02)11789-2","volume":"360","author":"Role of nicorandil in ischaemic preconditioning","year":"2002","unstructured":"Role of nicorandil in ischaemic preconditioning (2002) The Lancet 360(9348):1888. https:\/\/doi.org\/10.1016\/S0140-6736(02)11789-2","journal-title":"The Lancet"},{"key":"4409_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199206203-00008","author":"A Frydman","year":"1992","unstructured":"Frydman A (1992) Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol. https:\/\/doi.org\/10.1097\/00005344-199206203-00008","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"4409_CR52","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/17512433.2018.1508342","volume":"11","author":"Y Li","year":"2018","unstructured":"Li Y, Liu H, Peng W, Song Z (2018) Nicorandil improves clinical outcomes in patients with stable angina pectoris requiring PCI: a systematic review and meta-analysis of 14 randomized trials. Expert Rev Clin Pharmacol 11(9):855\u2013865. https:\/\/doi.org\/10.1080\/17512433.2018.1508342","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"4409_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clinthera.2007.12.020","volume":"29","author":"H Ishii","year":"2007","unstructured":"Ishii H, Toriyama T, Aoyama T et al (2007) Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 29(1):110\u2013122. https:\/\/doi.org\/10.1016\/j.clinthera.2007.12.020","journal-title":"Clin Ther"},{"issue":"4","key":"4409_CR54","doi-asserted-by":"publisher","first-page":"c301","DOI":"10.1159\/000329112","volume":"119","author":"M Nishimura","year":"2011","unstructured":"Nishimura M, Sakoda C, Murakawa M et al (2011) Oral nicorandil for prevention of cardiac death in hemodialysis patients without obstructive coronary artery disease: a propensity-matched patient analysis. Nephron Clin Pract 119(4):c301\u2013c309. https:\/\/doi.org\/10.1159\/000329112","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"4409_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/XCE.0000000000000187","volume":"9","author":"O Baydar","year":"2020","unstructured":"Baydar O, Kilic A (2020) Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction. Cardiovasc Endocrinol Metab 9(1):24\u201329. https:\/\/doi.org\/10.1097\/XCE.0000000000000187","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"4409_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-021-01021-1","author":"Z Lun","year":"2021","unstructured":"Lun Z, Liu L, Chen G et al (2021) The global incidence and mortality of contrast-associated acute kidney injury following coronary angiography: a meta-analysis of 1.2 million patients. J Nephrol. https:\/\/doi.org\/10.1007\/s40620-021-01021-1","journal-title":"J Nephrol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04409-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04409-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T04:16:23Z","timestamp":1749874583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04409-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":56,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["4409"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04409-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.09.15.24313706","asserted-by":"object"}]},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report no relationships that could be construed as a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}